News
NICE ‘no’ for Opdivo/Yervoy lung cancer combo
The National Institute for Health and Care Excellence (NICE) has issued a preliminary no for NHS use of Bristol-Myers Squibb’s Opdivo (nivolumab)/Yervoy (ipilimumab) combination for treating a certain lung cancer.